Literature summary for 1.3.1.2 extracted from

Balzarini, J.; Sienaert, R.; Liekens, S.; Van Kuilenburg, A.; Carangio, A.; Esnouf, R.; De Clercq, E.; McGuigan, C.
Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase (2002), Mol. Pharmacol., 61, 1140-1145.

Search for more literature for 1.3.1.2

Inhibitors

Inhibitors	Comment	Organism	Structure
(E)-5-[2-bromovinyl-]uracil	50% inhibition at 0.01 mM, no inhibition by free base	Homo sapiens
(E)-5-[2-bromovinyl-]uracil	50% inhibition at 0.01 mM, no inhibition by free base	Mus musculus

Natural Substrates/ Products (Substrates)

Natural Substrates	Organism	Comment (Nat. Sub.)	Natural Products	Comment (Nat. Pro.)	Rev.	Reac.
thymine + NADPH	Mus musculus	-	dihydrothymine + NADP+	-	r
thymine + NADPH	Homo sapiens	-	dihydrothymine + NADP+	-	r
uracil + NADPH	Mus musculus	-	5,6-dihydrouracil + NADP+	-	?
uracil + NADPH	Homo sapiens	-	5,6-dihydrouracil + NADP+	-	r

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-
Mus musculus	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
blood	-	Homo sapiens	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
5-fluorouracil + NADPH + H+	-	Mus musculus	5-fluoro-5,6-dihydrouracil + NADP+	-	?
5-fluorouracil + NADPH + H+	-	Homo sapiens	5-fluoro-5,6-dihydrouracil + NADP+	-	?
thymine + NADPH	-	Mus musculus	dihydrothymine + NADP+	-	?
thymine + NADPH	-	Mus musculus	dihydrothymine + NADP+	-	r
thymine + NADPH	-	Homo sapiens	dihydrothymine + NADP+	-	?
thymine + NADPH	-	Homo sapiens	dihydrothymine + NADP+	-	r
uracil + NADPH	-	Mus musculus	5,6-dihydrouracil + NADP+	-	?
uracil + NADPH	-	Homo sapiens	5,6-dihydrouracil + NADP+	-	r

Cofactor

Cofactor	Comment	Organism	Structure
NADPH	-	Mus musculus
NADPH	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)